Another study showed that ALKBH5 enhanced anti-PD-1 therapy response by regulating Mct4/Slc16a3 expression and lactate content and the composition of tumor-infiltrating Tregs and myeloid-derived suppressor cells in the tumor microenvironment 115. This evidence concerns the gene SLC16A3 and neoplasm.